Key takeaways
- Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on both GIP and GLP-1 receptors.
- Both titrate, so both require dose-aware billing tied to the ship event rather than a calendar.
- Both injectables are temperature-sensitive, so both constrain routing to cold-chain-qualified pharmacies.
- Tirzepatide typically carries a higher retail price, which changes contribution margin and payback.
- Oral formats exist for semaglutide and remove the cold-chain constraint entirely.
The clinical difference, briefly
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist acting on both GIP and GLP-1 receptors. Both slow gastric emptying and act on appetite regulation, and both are titrated upward over months as tolerance allows.
Prescribing between them is a clinical decision for the licensed provider based on the individual patient, and nothing on this page is medical guidance. What follows is what the difference means operationally.
Both titrate, which is the operational headline
The dose changes over the patient's life for both compounds. That means the product being shipped in month eight is not the product shipped in month one, and the invoice has to follow it.
A calendar-based subscription cannot express this. Billing has to fire on the day the pharmacy ships, at the dose actually dispensed, with a provider-reviewed check-in gating the step up.
Fulfillment and cold chain
Both injectable formats are temperature-sensitive and route only to cold-chain-qualified pharmacies. That constrains your real state coverage to the qualified subset of your network, which is a smaller number than your licensure map suggests.
Oral semaglutide formats avoid the constraint entirely, which is why they are often the better option for states where cold-chain coverage is thin, and why offering both formats widens your addressable map.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GIP and GLP-1 dual agonist |
| Injectable | Yes, cold chain | Yes, cold chain |
| Oral format available | Yes | Less commonly |
| Titration | Yes, stepped | Yes, stepped |
| Typical retail position | Lower | Higher |
| Cold chain constrains coverage | Injectable only | Yes |
What the price difference does to your model
Tirzepatide typically carries a higher retail price than semaglutide. On the same patient count that is a higher gross billing figure, but contribution margin depends on your landed fulfillment cost, which also differs.
The mistake is assuming higher price means better economics. Compute contribution per patient per month for each compound separately, then payback period against blended acquisition cost. They can rank differently than revenue suggests.
Offer both, and let the provider choose
Commercially, carrying both compounds and both formats widens the set of patients you can serve and the states you can serve them in. Clinically, the selection belongs to the provider reviewing the individual case.
The infrastructure requirement is that your catalog, intake, routing and billing all handle both without separate workflows, and that your storefront describes compounded preparations accurately rather than implying equivalence to branded products.
Both compounds, both formats, one workflow
PharmaBro routes semaglutide and tirzepatide in injectable and oral formats across cold-chain-qualified pharmacies per SKU and state, with dose-aware billing that fires on the ship event.
Zero medication markup, so routing optimises for your landed cost and you keep the entire spread against whatever retail price you set.
Conclusion
For an operator the difference between these two compounds is less clinical than it is logistical and financial.
Both titrate, so both need ship-date billing. Both injectables need cold chain, so both constrain coverage. They differ on price point and therefore on contribution, which is worth computing separately rather than assuming.
Frequently asked questions
What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist; tirzepatide acts on both GIP and GLP-1 receptors. Both are titrated upward over months. Selection between them is a clinical decision for the licensed provider based on the individual patient.
Do both need cold chain shipping?
The injectable formats of both are temperature-sensitive and must route to cold-chain-qualified pharmacies. Oral semaglutide formats remove that constraint, which widens the states you can reliably serve.
Which is better for a telehealth brand to offer?
Both, where clinically appropriate. Carrying both compounds and both formats widens the patients and states you can serve. Compute contribution margin per compound separately rather than assuming the higher-priced one is the better business.
References
Dana WhitfieldDirector of Pharmacy Operations
Runs the pharmacy network and the routing layer. Has negotiated enough fulfillment agreements to have strong opinions about why launches actually slip.